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Although clearance of b2-microglobulin is greater with
hemodiafiltration than with high-flux hemodialysis,
b2-microglobulin concentrations after long-term
hemodiafiltration are only slightly less than those obtained
with high-flux hemodialysis. Resistance to b2-microglobulin
transfer between body compartments could explain this
observation. b2-Microglobulin kinetics were determined in
patients receiving on-line post-dilution hemodiafiltration
for 4 h with 18 l of filtration. Plasma b2-microglobulin
concentrations were measured during and for 2 h following
hemodiafiltration and immediately before the next
treatment. The filter clearance of b2-microglobulin was
determined from arterial and venous concentrations. The
b2-microglobulin generation rate was calculated from the
change in the plasma concentration between treatments.
The intercompartmental clearance was obtained by fitting
the observed concentrations to a two-compartment, variable
volume model. The plasma clearance of b2-microglobulin by
the filter was 7372 ml/min. Plasma b2-microglobulin
concentrations decreased by 6872% from pre- to
post-treatment (27.172.2–8.570.7 mg/l), but rebounded by
3273% over the next 90 min. The generation rate of
b2-microglobulin was 0.13670.008 mg/min. The model fit
yielded an intercompartmental clearance of 8277 ml/min
and a volume of distribution of 10.270.6 l, corresponding to
14.370.7% of body weight. Hemodiafiltration provides a
b2-microglobulin clearance of similar magnitude to the
intercompartmental clearance within the body. As a result,
intercompartmental mass transfer limits b2-microglobulin
removal by hemodiafiltration. This finding suggests that
alternative strategies, such as increased treatment times or
frequency of treatment, are needed to further reduce plasma
b2-microglobulin concentrations.
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b2-Microglobulin is an 11.8 kDa protein that comprises the
light chain of the major histocompatibility complex present
on the surface of all cells. After being shed from the cell
surface, b2-microglobulin is eliminated from the circulation
by glomerular filtration, followed by reabsorption and
catabolism in the proximal tubule. As renal function
decreases, b2-microglobulin is retained in the plasma and
deposits as amyloid fibrils in many tissues. These amyloid
deposits may cause carpal tunnel syndrome, arthropathy and
bone cysts, and are a cause of morbidity in long-term
hemodialysis patients.1
In general, the clearance of b2-microglobulin by hemo-
dialysis with low-flux membranes is negligible.2,3 Clearance
of b2-microglobulin by high-flux membranes is reported to
be in the range of 17–22 ml/min;2,3 however, the rapid
decrease in diffusive permeability with increasing molecular
size limits b2-microglobulin clearance by diffusion no matter
which membrane is used. To address the limited
b2-microglobulin removal that can be obtained by diffusion,
several investigators have turned to therapies based on
convection, such as hemodiafiltration4–8 or adsorption.9,10
Hemodiafiltration provides dialyzer clearances of b2-micro-
globulin that are approximately twice those obtained with
high-flux hemodialysis.7,11 In spite of this difference,
predialysis b2-microglobulin concentrations remain at about
20 mg/l following long-term on-line hemodiafiltration,4–8 a
level that is not markedly lower than that achievable with
high-flux hemodialysis when comparable blood flow rates
and membrane surface areas are used.7
It has long been recognized that disequilibrium develops
between body compartments when dialytic removal exceeds
the rate of transfer of solute from the extravascular
compartment into the plasma.12 This disequilibrium leads
to a rebound in plasma concentrations, post-dialysis, as the
solute re-equilibrates between compartments once dialytic
removal ceases. Previous studies have shown a rebound in
plasma b2-microglobulin concentrations following modestly
efficient high-flux hemodialysis.13–15 Therefore, we hypothe-
sized that the inability of long-term hemodiafiltration to
markedly reduce plasma b2-microglobulin concentrations is a
consequence of a significant mass transfer resistance between
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the vascular and extravascular compartments. To test this
hypothesis, we determined the intercompartmental mass
transfer coefficient for b2-microglobulin using plasma
concentrations of b2-microglobulin obtained during and
immediately following hemodiafiltration and a two-compart-
ment kinetics model. The model was then used to assess the
impact of changes in extracorporeal clearance and treatment
frequency on b2-microglobulin removal.
RESULTS
Ten patients (eight men and two women) were enrolled in the
study. The patients ranged in age from 28 to 70 years (mean
56 years) and the etiology of their renal failure included
glomerulonephritis (two patients), diabetes (two patients),
hypertension (two patients), polycystic kidney disease (one
patient) and was unknown for three patients. At the time of
the study, nine of the patients were being treated with high-
flux hemodialysis and one with hemodiafiltration. The
duration of their dialysis therapy ranged from 24 to 74
months (mean 49 months).
Details of the study treatments are given in Table 1. The
treatment dose, as determined by the equilibrated Kt/V for
urea,16 was 1.2170.07. The plasma clearance of b2-micro-
globulin determined after 60 min of hemodiafiltration was
7372 ml/min (equivalent to a whole blood clearance of
10974 ml/min). b2-Microglobulin concentrations decreased
by 6872% during hemodiafiltration from 27.172.2 to
8.570.7 mg/l, then rebounded by 3273%, corrected for
generation, over the next 90 min by which time the rebound
was complete (Figure 1). The post-hemodiafiltration con-
centration corrected for hemoconcentration by the method
of Bergstro¨m and Wehle17 was 7.470.6 mg/l. The inter-
compartmental clearance and volume of distribution were
estimated by fitting the model to the measured b2-micro-
globulin concentrations for each patient. Overall, the
estimated intercompartmental clearance was 8277 ml/min
and the estimated volume of distribution was 10.270.6 l,
corresponding to 14.370.7% of body weight. Estimated
values of the two parameters for the individual patients
are given in Table 2. Figure 2 presents the measured
and modeled b2-microglobulin concentrations for a typical
patient. The overall generation rate of b2-microglobulin,
calculated using the estimated volume of distribution, was
0.13670.008 mg/min.
DISCUSSION
Developing treatment strategies to remove b2-microglobulin,
and thereby prevent or slow amyloid formation in patients
with end-stage renal disease, requires an understanding of
Table 1 | Details of study treatments
Treatment time (TD, min) 240
Blood flow rate (QB, ml/min) 280
Hematocrit (t=60) (Hct) 0.3570.01
Plasma flow rate (t=60) (QP, ml/min)
a 18273
Weight, pretreatment (kg) 73.473.2
Weight, post-treatment (kg) 71.273.3
Net ultrafiltration rate (QUF, ml/min) 9.171.4
Total ultrafiltered volume (l) 18
Interdialytic interval (TID, min) 23277165
Weight, post-interdialytic interval (kg) 73.773.1
Inter-dialytic fluid gain (a, ml/min) 1.1470.16
Data are presented as mean7s.e.m. for n=10.
aPlasma flow rate (QP) was determined from the blood flow rate (QB) and the
fractional hematocrit (Hct) at the inlet to the hemodiafilter as QP=QB (1–Hct).
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Figure 1 | Plasma b2-microglobulin concentrations during a 4-h
hemodiafiltration treatment and for 2-h following hemodiafil-
tration. Data are presented as mean7s.e.m. for 10 patients.
Table 2 | Estimated kinetic model parameters for b2-micro-
globulin
Patient
Intercompartmental
Clearance,
KIC (ml/min)
Distribution
volume, VD=VP+VNP (l)
Generation rate,
G (mg/min)
1 100 13.27 0.131
2 86 7.52 0.131
3 63 8.10 0.144
4 75 12.31 0.091
5 53 8.57 0.140
6 57 9.25 0.125
7 108 11.99 0.131
8 102 9.91 0.165
9 74 9.31 0.182
10 107 11.37 0.115
Data are presented as mean7s.e.m. for n=10.
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Figure 2 | Concentration profiles of b2-microglobulin in the
perfused (solid line) and non-perfused (broken line) compart-
ments obtained by fitting the kinetic model to measured plasma
concentrations of b2-microglobulin (K) for a typical patient.
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b2-microglobulin kinetics. Various kinetic models have been
developed to describe b2-microglobulin kinetics during
hemodialysis2,18–21 and some of these models have been used
to simulate b2-microglobulin removal with different treat-
ment strategies.2,22 Two-compartment models have been the
most widely used.18–20,22 Single-compartment models are too
simplistic based on the observation of a significant post-
dialysis rebound in plasma b2-microglobulin concentration
immediately following high-flux hemodialysis (Figure 1 and
Yasuhiro et al.14), while models with three or more
compartments suffer from problems of parameter estimation.
The utility of two-compartment models depends on the
estimation of several parameters that cannot be measured
directly, including the compartment volumes, the inter-
compartmental clearance and the generation rate of b2-
microglobulin. Previous efforts to estimate these parameters
have relied on infusing 125I-b2-microglobulin and fitting the
plasma disappearance curve to the model.2,23,24 This method
has several drawbacks, including the need to prepare and
infuse radiolabeled protein, the need to separate free 125I
from 125I-b2-microglobulin in plasma samples and the
assumption that kinetics following intravenous injection are
the same as those occurring during and after an extracorpor-
eal blood purification treatment. An alternative strategy
involves fitting the model equations to plasma solute
concentrations measured during and immediately following
hemodialysis. The usefulness of this method has been limited
by the relatively small reduction in plasma b2-microglobulin
concentration that is effected by dialysis even with high-flux
membranes.2,14 Hemodiafiltration causes a much more
pronounced decrease in plasma b2-microglobulin concentra-
tions than does high-flux hemodialysis,7 making the latter
approach more amenable to estimating the model para-
meters.
The model for b2-microglobulin kinetics used in this
study differs from the two-pool models used by other
investigators in several ways. In the present work, generation
of b2-microglobulin was assumed to occur in both the
perfused and the non-perfused compartments. Previous
investigators have assumed that b2-microglobulin is gener-
ated in only one compartment.2,18–22 However, b2-micro-
globulin is expressed on the surface of most nucleated cells
making it more likely that free b2-microglobulin is generated
in both compartments. Most prior investigations2,18,22 have
assumed that mass transfer of b2-microglobulin between the
two compartments occurs by diffusion, only. We, along with
Gotch and Keen,25 have assumed that mass transfer also
occurs by convection in conjunction with fluid movement
between the two compartments. Finally, many prior studies
of b2-microglobulin kinetics have assumed that the distribu-
tion volume for b2-microglobulin corresponds to extracel-
lular fluid and they have also assumed that volume to be
equal to one-third of the total body water.18,20–22 We allowed
the volume of distribution to vary and obtained an estimate
based on the best fit of the model equations to the
experimental data.
The observed rebound in plasma b2-microglobulin
concentration following hemodiafiltration was similar to
that observed by Yasuhiro et al.14 following high-flux
hemodialysis, 31 versus 24%, respectively. The volume of
distribution for b2-microglobulin derived from fitting the
model to the experimental data was significantly less than
that estimated from the anthropometric formulae of Watson
et al.26 (10.270.6 l or 14.370.7% of body weight compared
to 12.870.6 l or 18.070.4% of body weight, P¼ 0.0016).
A similar discrepancy between the volume of distribution
derived from experimental data and that calculated from
anthropometric relationships has also been observed for
urea.27,28 The reasons for these differences are not known,
but may include failure of the anthropometric method to
account for the protein content of the plasma.27,28 The
calculated generation of b2-microglobulin (0.13670.008 mg/
day) is similar to that determined in normal subjects
(0.16270.016 mg/min29) and in dialysis patients using
radiolabeled b2-microglobulin (0.15870.015 mg/min,
2
0.18070.024 mg/min,23 0.14870.009 mg/min24), and in
hemodialysis patients using methods similar to ours
(0.13270.006 mg/min,13 0.08870.003 mg/min30). The esti-
mated intercompartmental clearance for b2-microglobulin
was 8277 ml/min, similar to the 6675 ml/min obtained by
Floege et al.24 following infusion of radiolabeled b2-micro-
globulin.
Our model incorporates assumptions that may limit its
applicability. Two assumptions concern fluid and solute
transport between the perfused and non-perfused compart-
ments. Changes in total fluid volume are assumed to be
distributed between the perfused and non-perfused compart-
ments in proportion to their volumes with no delay in fluid
movement between the compartments. Delayed vascular
refilling in response to ultrafiltration during a treatment
would violate this assumption and reduce the accuracy of the
model. A delay in vascular refilling would be marked by an
increase in plasma protein concentration during the treat-
ment followed by a prompt decrease in the immediate post-
treatment period. We observed a small increase in serum
albumin concentration during hemodiafiltration (3.770.2 to
3.970.2 g/dl) and no decrease in the immediate post-
treatment period, indicating no delay in vascular refilling.
Leypoldt et al. obtained a similar result in one study of high-
flux hemodialysis,15 but not in another,31 suggesting that
delayed vascular refilling may occur under some circum-
stances. The nature of these circumstances is unclear, making
it difficult to incorporate a lag term in the equations used to
describe compartment volumes as a function of time. Unlike
some previous models of b2-microglobulin kinetics,
2,18,22 our
model assumes that solute transfer between the perfused and
non-perfused compartments occurs by both diffusion and
convection. The perfused and non-perfused compartments
are generally assumed to represent plasma and the inter-
stitium, in which case the transfer barrier is the capillary wall.
We are unaware of any sieving coefficient data for low
molecular weight proteins, such as b2-microglobulin, and the
Kidney International (2006) 69, 1431–1437 1433
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capillary wall. Harper et al.32 have shown that a uremic
environment significantly increases the protein permeability
of the microvasculature. Given this observation, and in the
absence of data, we have assumed that the sieving coefficient
of the transfer barrier between the two compartments for
b2-microglobulin is one. The impact of these two assump-
tions on the accuracy of the model is likely to depend
on the magnitude of the ultrafiltration rate, with the impact
being limited at the low net ultrafiltration rates used in
our study.
Another assumption in our model is that the extracorpor-
eal clearance of b2-microglobulin is constant throughout the
treatment. In hemodiafiltration, clearance of b2-microglobu-
lin occurs through a combination of convection, diffusion
and adsorption to the membrane. We combined these three
mechanisms into a single total clearance, which was
measured after 1 h of treatment. We have found that the
clearance of the Polyflux S membrane used in this study
remains essentially constant over the course of a single
treatment given constant operating conditions (unpublished
observations). However, this observation may not hold true
for other membranes. Moreover, the practice of dialyzer reuse
has been associated with both increases and decreases in
b2-microglobulin clearance from treatment to treatment,
33
which would impact the accuracy of the model predictions
shown in Figure 3 if hemodiafiltration was performed with
reused hemodiafilters.
Recognizing that convection provides higher clearances of
large solutes, such as b2-microglobulin, many investigators
have turned to hemofiltration and hemodiafiltration in the
expectation that these therapies would decrease plasma
b2-microglobulin concentrations and ameliorate the adverse
effects of b2-microglobulin amyloid in long-term end-stage
renal disease patients. The benefits obtained with these
therapies, however, have been relatively modest, at least in
terms of reducing pre-treatment plasma b2-microglobulin
concentrations below those obtained with high-flux hemo-
dialysis.4,5,7 Even with 60 l of convection in the post-dilution
mode, Wizemann et al.6 could not reduce the pretreatment
b2-microglobulin concentration below about 18 mg/l after 24
months. (It should be noted that the predialysis concentra-
tions of b2-microglobulin reported in Figures 1 and 2
indicate nothing about the long-term effectiveness of
hemodiafiltration because, with one exception, the patients
participating in this study were normally treated with high-
flux hemodialysis.)
Our results show that the extracorporeal plasma clearance
of b2-microglobulin obtained with hemodiafiltration
(7372 ml/min) approached the intercompartmental clear-
ance (8277 ml/min). Our kinetic analysis also shows that a
substantial disequilibrium develops between the perfused and
non-perfused compartments when the extracorporeal clear-
ance and the intercompartmental clearance are similar in
magnitude (Figure 2). The extent of this disequilibrium will
increase as the extracorporeal clearance is increased relative
to the intercompartmental clearance and the return on
increasing the extracorporeal clearance will be limited as the
greatest resistance to mass transfer limits solute removal. This
situation is shown in Figure 3a, which depicts the plasma
b2-microglobulin concentration profile predicted using our
model over a 1-week period for thrice-weekly high-flux
hemodialysis (extracorporeal clearance 25 ml/min), hemo-
diafiltration (extracorporeal clearance 75 ml/min) and hemo-
adsorption (extracorporeal clearance 150 ml/min). These
calculated profiles show a diminishing return in terms of
reducing the plasma b2-microglobulin concentration as
clearance increases and suggest that the benefits to be derived
from hemoadsorption may be limited. On the other hand,
application of our model suggests that increasing the
frequency of treatment may have a marked effect on the
plasma concentration of b2-microglobulin (Figure 3b). The
model predicts mid-week serum b2-microglobulin concen-
trations of 23 and 17 mg/l for 2 h of hemodiafiltration and 8 h
of high-flux hemodialysis, 6 days per week, respectively,
compared to 25 mg/l for 4 h of hemodiafiltration, 3 days per
week. These model predictions are in good agreement with
clinical observations reported in the literature. We have
previously reported a mid-week serum b2-microglobulin
concentration of 23 mg/l in 24 patients treated with thrice-
weekly on-line hemodiafiltration for 12 months.7 Maduell
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Figure 3 | (a) Predicted plasma b2-microglobulin concentration
profiles over a one week period for thrice weekly high-flux
hemodialysis (KD¼ 25 ml/min, dashed line), hemodiafiltration
(KD¼ 75 ml/min, dotted line) and hemoadsorption (KD¼ 150 ml/
min, solid line). (b) Predicted plasma b2-microglobulin concentration
profiles over a 1-week period for three 4-h hemodiafiltration
treatments (KD¼ 75 ml/min, dotted line), six 2-h hemodiafiltration
treatments (KD¼ 75 ml/min, solid line) or six 8-h high-flux hemodia-
lysis treatments (KD¼ 25 ml/min, dashed line). All simulations assume
a distribution volume of 10 l, a generation rate of 0.14 mg/min, an
intercompartmental clearance of 82 ml/min, a non-renal clearance of
3 ml/min and a weekly fluid removal volume of 9 l.
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et al.34 reported a mid-week serum b2-microglobulin
concentration of 23 mg/l in eight patients treated for 6
months with 2–2.5 h of on-line hemodiafiltration 6 days per
week, whereas Canaud et al.35 reported a concentration of
around 25 mg/l in seven patients treated daily with 3 h of
hemofiltration. It should be noted that the b2-microglobulin
clearance was lower in the latter study than is assumed in
Figure 3. Finally, Raj et al.36 reported a mid-week serum
b2-microglobulin concentration of 14 mg/l in 13 patients
treated for 9 months with 8 h of high-flux hemodialysis six
nights per week.
In summary, the results of this kinetic study suggest that
the development of on-line convective therapies, such as
hemodiafiltration, has led to the situation where b2-micro-
globulin removal is controlled as much by intercompart-
mental transfer within the body as by the extracorporeal
clearance of b2-microglobulin. This finding, as illustrated by
the simulations in Figure 3, suggests that returning serum
b2-microglobulin concentrations to a more normal level will
be best achieved by concentrating on the time and frequency
of therapy rather than through strategies designed to increase
the extracorporeal clearance.
MATERIALS AND METHODS
Experimental design
Plasma b2-microglobulin concentrations were determined during a
single mid-week hemodiafiltration treatment and the following
intertreatment period. Hemodiafiltration was performed in the
post-dilution mode using on-line preparation of substitution
solution (AK 100 ULTRA, Gambro, Hechingen, Germany). All
treatments were performed with dialyzers containing high-flux
membranes based on polyarylethersulfone (Polyflux 17S, Gambro).
The treatment time was 240 min, with blood and total dialysate flow
rates fixed at 280 and 500 ml/min, respectively. The total filtration
volume was set at 18 l. Net fluid removal was set according to the
patients’ clinical needs. Other aspects of the treatment were
according to the patient’s routine prescription. Patients were
required to have a hematocrit of at least 30% and a blood access
capable of delivering a flow rate of 280 ml/min to be eligible for
participation in the study. Exclusion criteria included a residual
urine output of more than 200 ml/day or an infection within 30 days
of the study.
Blood samples were collected following insertion of the first
access needle and from the arterial blood line after 60, 120 and
240 min of hemodiafiltration. A venous blood sample was also
collected at 60 min to allow calculation of the plasma water clearance
of b2-microglobulin by the dialyzer. Immediately after collection of
the 240 min blood sample, the blood flow rate was reduced to 80 ml/
min and a blood sample was collected 20 s later. Subsequent blood
samples were obtained at 5, 10, 30, 60, 90, 120, and 240 min after the
end of the treatment, and immediately before the next treatment. All
samples were placed in tubes containing ethylenediaminetetraacetic
acid and the plasma was separated by centrifugation. Samples were
stored at 701C until analysis for b2-microglobulin by nephelo-
metry.
The Ethics Committee of the University of Munich reviewed the
study protocol and each patient gave informed consent before
participating in the study.
Kinetic modeling
b2-Microglobulin kinetics were determined using a modification of a
two-pool model previously described by Kanamori and Sakai18
(Figure 4). The model assumes that b2-microglobulin is distributed in
two compartments: a perfused compartment, to which the dialyzer
has direct access, and a non-perfused compartment. Transfer of b2-
microglobulin between the two compartments is assumed to occur by
diffusion, with an intercompartmental clearance, KIC, and convection,
with an intercompartmental sieving coefficient of one. Generation
(G) is assumed to occur in both compartments in proportion to their
volumes. Non-renal clearance (KNR) of b2-microglobulin is assumed
to occur in the perfused compartment. The change in mass of
b2-microglobulin in the two compartments can be described as a
function of time (t) by the following two equations.
Perfused compartment
d VPCPð Þ
dt
¼FPG þ KICðCNP  CPÞ YKDCP  KNRCP
þYFNPQUFCNP  ð1 YÞFNPaCP
ð1Þ
Non-perfused compartment
dðVNPCNPÞ
dt
¼FNPG þ KICðCP  CNPÞ YFNPQUFCNP
þ ð1 YÞFNPaCP
ð2Þ
where VP and VNP are the volumes of the perfused and non-perfused
compartments, respectively, CP and CNP are the concentrations in
the perfused and non-perfused compartments, respectively, KD is
the dialyzer clearance, QUF is the ultrafiltration rate, a is the rate of
fluid intake in the interdialytic period, FP and FNP are the fractions
of the total distribution volume in the perfused and non-perfused
compartments, respectively, and, Y is an indicator variable such that
Y¼ 1 during dialysis and Y¼ 0 in the interdialytic period.
A similar pair of equations describes the change in volume of the
two compartments during dialysis as a function of time.
Intradialytic fluid removal and interdialytic fluid intake are assumed
to occur in both the perfused and non-perfused compartments in
proportion to their relative volumes.
Perfused compartment
dVP
dt
¼ YFPQUF þ ð1 YÞFPa ð3Þ
Nonperfused compartment
dVNP
dt
¼ YFNPQUF þ ð1 YÞFNPa ð4Þ
 NPG  PG
VNP, C NP VP, CP
KIC
K NR
KD
QUF
Dialyzer
Figure 4 | Schematic representation of the two-pool model for
b2-microglobulin kinetics. See text for an explanation of the
symbols.
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The generation rate of b2-microglobulin (G) was calculated from the
distribution volume (VD¼VPþVNP) and the change in plasma
concentration between the end of the post-treatment rebound and
the beginning of the next treatment. For this purpose, the post-
treatment rebound was assumed to be complete 240 min after the
end of the treatment.
G ¼
ðKNR þ aÞ CNEXT  C480 VD480=VDNEXTð ÞðKNRþaÞ=a
 
1  VD480=VDNEXTð ÞðKNRþaÞ=a
where the subscripts 480 and NEXT refer to 240 min after the end of
the treatment and the beginning of the next treatment, respectively.
The plasma clearance of b2-microglobulin by the dialyzer, KD,
was calculated using the following standard equation for clearance:
KD ¼ QBð1  HctÞ ðCA  CVÞ
CA
þ QUF CV
CA
where QB is the blood flow rate, Hct is the fractional hematocrit, and
CA and CV are the b2-microglobulin concentrations at the inlet and
the outlet of the dialyzer, respectively.
The non-renal clearance of b2-microglobulin, KNR, was assumed
to be 3 ml/min.2,37
Equations (1)–(4) were solved numerically using a fourth order
Runge–Kutta method.38 The ratio of the perfused volume to the
non-perfused volume was assumed to be 1:3, such that FP¼ 0.25
and FNP¼ 0.75. The intercompartmental clearance, KIC, and the
volume of distribution, VD¼VPþVNP, were estimated by determin-
ing the best fit of the equations to the plasma concentration versus
time data using a least-squares method.
The rebound in plasma b2-microglobulin concentration follow-
ing the end of hemodiafiltration was calculated as
Percent Rebound ¼ 100ðCT  C240Þ
C240
where C240 and CT are the solute concentrations at the end of dialysis
and T minutes after the end of dialysis, respectively.
Data are presented as mean7s.e.m. for n observations.
ACKNOWLEDGMENTS
We thank Christina Dengler for her help in sample collection and
analysis and the nursing staff of the KfH Kidney Center Neuried.
REFERENCES
1. Miyata T, Jadoul M, Kurokawa K, van Ypersele de Strihou C.
b2 microglobulin in renal disease. J Am Soc Nephrol 1998; 9: 1723–1735.
2. Odell RA, Slowiaczek P, Moran JE, Schindhelm K. Beta2-microglobulin
kinetics in end-stage renal failure. Kidney Int 1991; 39: 909–919.
3. Leypoldt JK, Cheung AK, Deeter RB. Single compartment models for
evaluating b2-microglobulin clearance during hemodialysis. ASAIO J 1997;
43: 904–909.
4. Kerr PB, Argile´s A, Flavier J-L et al. Comparison of hemodialysis and
hemodiafiltration: a long-term longitudinal study. Kidney Int 1992; 41:
1035–1040.
5. Locatelli F, Mastrangelo F, Redaelli B et al. Effects of different membranes
and dialysis technologies on patient treatment tolerance and nutritional
parameters. Kidney Int 1996; 50: 1293–1302.
6. Wizemann V, Lotz C, Techert F, Uthoff S. On-line hemodiafiltration versus
low-flux haemodialysis. A prospective randomized study. Nephrol Dial
Transplant 2000; 15(Suppl 1): 43–48.
7. Ward RA, Schmidt B, Hullin J et al. A comparison of on-line
hemodiafiltration and high-flux hemodialysis: a prospective clinical
study. J Am Soc Nephrol 2000; 11: 2344–2350.
8. Lin C-L, Yang C-W, Chiang C-C et al. Long-term on-line hemodiafiltration
reduces predialysis beta-2-microglobulin levels in chronic hemodialysis
patients. Blood Purif 2001; 19: 301–307.
9. Gejyo F, Teramura T, Ei I et al. Long-term clinical evaluation of an
adsorbent column (BM-01) of direct hemoperfusion type for
b2-microobulin on the treatment of dialysis-related amyloidosis. Artif
Organs 1995; 19: 1222–1226.
10. Ronco C, Brendolan A, Winchester JF et al. First clinical experience
with an adjunctive hemoperfusion device designed specifically
to remove b2-microglobulin in hemodialysis. Blood Purif 2001; 19:
260–263.
11. Lornoy W, Becaus I, Billiouw J-M et al. Remarkable removal of
beta-2-microglobulin by on-line hemodiafiltration. Am J Nephrol 1998;
18: 105–108.
12. Popovich RP, Hlavinka DJ, Bomar JB et al. The consequences of
physiological resistances on metabolite removal from the
patient–artificial kidney system. Trans Am Soc Artif Int Organs 1975;
21: 108–115.
13. Maeda K, Shinzato T, Ota T et al. Beta-2-microglobulin generation rate
and clearance rate in maintenance hemodialysis patients. Nephron 1990;
56: 118–125.
14. Yasuhiro I, Eiichi N, Mineo O et al. Removal of serum beta-2 microglobulin
using high-performance membranes and analysis of changes in serum
BMG levels after dialysis. Am J Nephrol 1998; 18: 228–232.
15. Leypoldt JK, Cheung AK, Deeter RB. Rebound kinetics of b2-microglobulin
after hemodialysis. Kidney Int 1999; 56: 1571–1577.
16. Daugirdas JT, Schneditz D. Overestimation of hemodialysis dose depends
on dialysis efficiency by regional blood flow but not by conventional two
pool urea kinetic analysis. ASAIO J 1995; 41: M719–M724.
17. Bergstro¨m J, Wehle B. No change in corrected b2-microglobulin
concentration after Cuprophane haemodialysis. Lancet 1987; 1:
628–629.
18. Kanamori T, Sakai K. An estimate of b2-microglobulin deposition rate in
uremic patients on hemodialysis using a mathematical kinetic model.
Kidney Int 1995; 47: 1453–1457.
19. Gotch F, Levin N, Zasuwa G, Tayeb J. Kinetics of beta-2-microglobulin in
hemodialysis. Contrib Nephrol 1989; 74: 132–138.
20. Lee CJ, Hsiong CH, Chang YL et al. Statistical and parametric analysis
of beta-2-microglobulin removal from uremic patients in high flux
hemodialysis. ASAIO J 1994; 40: 62–66.
21. Lian JD, Cheng CH, Chang YL et al. Clinical experience and model analysis
on beta-2-microglobulin kinetics in high-flux hemodialysis. Artif Organs
1993; 17: 758–763.
22. Clark WR, Leypoldt JK, Henderson LW et al. Quantifying the effect of
changes in the hemodialysis prescription on effective solute removal with
a mathematical model. J Am Soc Nephrol 1999; 10: 601–609.
23. Vincent C, Chanard J, Caudwell V et al. Kinetics of 125I-b2-microglobulin
turnover in dialyzed patients. Kidney Int 1992; 42: 1434–1443.
24. Floege J, Bartsch A, Schulze M et al. Clearance and synthesis rates of
b2-microglobulin in patients undergoing hemodialysis and in normal
subjects. J Lab Clin Med 1991; 118: 153–165.
25. Gotch FA, Keen ML. Kinetic modeling in hemodialysis. In Nissenson AR,
Fine RN (eds). Clinical Dialysis, 4th edn. McGraw-Hill: New York, 2005,
pp 153–202.
26. Watson PE, Watson ID, Batt RD. Total body water volumes for adult males
and females estimated from simple anthropometric measurements. Am J
Clin Nutr 1980; 33: 27–39.
27. Kloppenburg WD, Stegeman CA, de Jong PE, Huisman RM.
Anthropometry-based equations overestimate the urea distribution
volume in hemodialysis patients. Kidney Int 2001; 59: 1165–1174.
28. Daugirdas JT, Greene T, Depner TA et al. Anthropometrically estimated
total body water volumes are larger than modeled urea volume in
chronic hemodialysis patients: effects of age, race, and gender. Kidney Int
2003; 64: 1108–1119.
29. Karlsson FA, Groth T, Sege K et al. Turnover in humans of
b2-microglobulin: The constant chain of HLA antigens. Eur J Clin Invest
1980; 10: 293–300.
30. Xu XQ, Gruner N, Al-Bashir A et al. Determination of extra renal clearance
and generation rate of b2-microglobulin in hemodialysis patients using a
kinetic model. ASAIO J 2001; 47: 623–627.
31. Leypoldt JK, Cheung AK, Deeter RB et al. Kinetics of urea and
b2-microglobulin during and after short hemodialysis treatments. Kidney
Int 2004; 66: 1669–1676.
32. Harper SJ, Tomson CRV, Bates DO. Human uremic plasma increases
microvascular permeability to water and proteins in vivo. Kidney Int 2002;
61: 1416–1422.
33. Cheung AK, Agodoa LY, Daugirdas JT et al. Effects of hemodialyzer reuse
on clearances of urea and b2-microglobulin. J Am Soc Nephrol 1999; 10:
117–127.
1436 Kidney International (2006) 69, 1431–1437
o r i g i n a l a r t i c l e RA Ward et al.: Resistance to intercompartmental mass transfer
34. Maduell F, Navarro V, Torregrosa E et al. Change from three times a week
on-line hemodiafiltration to short daily on-line hemodiafiltration. Kidney
Int 2003; 64: 305–313.
35. Canaud B, Assounga A, Kerr P et al. Failure of a daily haemofiltration
programme using a highly permeable membrane to return
b2-microglobulin concentrations to normal in haemodialysis patients.
Nephrol Dial Transplant 1992; 7: 924–930.
36. Raj DSC, Ouwendyk M, Francoeur R, Pierratos A. b2-microglobulin
kinetics in nocturnal haemodialysis. Nephrol Dial Transplant 2000; 15:
58–64.
37. Floege J, Wilks M, Shaldon S et al. b2-Microglobulin kinetics during
haemofiltration. Nephrol Dial Transplant 1988; 3: 784–789.
38. Forsythe GE, Malcolm MA, Moler CB. Computer Methods for Mathematical
Computations. Prentice-Hall: Englewood Cliffs, NJ, 1977.
Kidney International (2006) 69, 1431–1437 1437
RA Ward et al.: Resistance to intercompartmental mass transfer o r i g i n a l a r t i c l e
